Abstract
Background: Besides the first-line medication for the treatment of type 2 diabetes, the growth inhibitory activity of metformin alone or in combination with conventional chemotherapeutics has been addressed on a panel of cell lines. In this study, we investigated the cytotoxicity and apoptosis of the metformin alone and in combination with dacarbazine in Raji and Ramos lymphoma cell lines.
Methods: Cell viability and apoptosis measured using resazurin assay, flow cytometry of PI stained cells and western blot analysis.
Results: Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone. The activation of MAPK and SAPK/JNK (P-SAPK/JNK) were shown in both cells.
Conclusion: Overall, the result verified the synergistic effect of the metformin-dacarbazine combination, which has the value in reducing the chemotherapeutic agent dose, adverse effect and the burden of treatment for the community and patients.
Keywords: Metformin, dacarbazine, lymphoma, cytotoxic, MAPK, apoptosis, synergistic effects.
Graphical Abstract
Current Molecular Pharmacology
Title:The Role of SAPK/JNK Pathway in the Synergistic Effects of Metformin and Dacarbazine on Apoptosis in Raji and Ramos Lymphoma Cells
Volume: 11
Author(s): Maryam Naserian, Elham Ramazani, Mehrdad Iranshahi and Zahra Tayarani-Najaran*
Affiliation:
- Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad,Iran
Keywords: Metformin, dacarbazine, lymphoma, cytotoxic, MAPK, apoptosis, synergistic effects.
Abstract: Background: Besides the first-line medication for the treatment of type 2 diabetes, the growth inhibitory activity of metformin alone or in combination with conventional chemotherapeutics has been addressed on a panel of cell lines. In this study, we investigated the cytotoxicity and apoptosis of the metformin alone and in combination with dacarbazine in Raji and Ramos lymphoma cell lines.
Methods: Cell viability and apoptosis measured using resazurin assay, flow cytometry of PI stained cells and western blot analysis.
Results: Metformin showed synergistic cytotoxic effects in combination with dacarbazine, reduced cell viability, and increased apoptosis in Raji and Ramos lymphoma cells in comparison with the use of each drug alone. The activation of MAPK and SAPK/JNK (P-SAPK/JNK) were shown in both cells.
Conclusion: Overall, the result verified the synergistic effect of the metformin-dacarbazine combination, which has the value in reducing the chemotherapeutic agent dose, adverse effect and the burden of treatment for the community and patients.
Export Options
About this article
Cite this article as:
Naserian Maryam , Ramazani Elham , Iranshahi Mehrdad and Tayarani-Najaran Zahra*, The Role of SAPK/JNK Pathway in the Synergistic Effects of Metformin and Dacarbazine on Apoptosis in Raji and Ramos Lymphoma Cells, Current Molecular Pharmacology 2018; 11 (4) . https://dx.doi.org/10.2174/1874467211666180830150546
DOI https://dx.doi.org/10.2174/1874467211666180830150546 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Biological and Pharmacological Roles of N6-Isopentenyladenosine: An Emerging Anticancer Drug
Anti-Cancer Agents in Medicinal Chemistry Regulation of p53 Activity
Current Chemical Biology Omalizumab for Asthma: Indications, Off-Label Uses and Future Directions
Recent Patents on Inflammation & Allergy Drug Discovery Ferroptosis Inducers for Prostate Cancer Therapy
Current Medicinal Chemistry Toxicogenomics to Evaluate Endocrine Disrupting Effects of Environmental Chemicals Using the Zebrafish Model
Current Genomics Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New Perspectives for Potential Applications
Current Pharmaceutical Design Current Concepts and Future Directions in Radioimmunotherapy
Current Drug Discovery Technologies Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology Alteration of Ceramide 1-O-Functionalization as a Promising Approach for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Anti-TNF and Crohns Disease: When Should we Start?
Current Drug Targets Oocyte Cryopreservation for Elective Preservation of Reproductive Potential
Current Women`s Health Reviews Developments Towards a Prophylactic Hepatitis C Virus Vaccine
Current Immunology Reviews (Discontinued) Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology Thalidomide Analogues as Anticancer Drugs
Recent Patents on Anti-Cancer Drug Discovery Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers
Current Pharmaceutical Biotechnology Epstein-Barr Virus-associated Gastric Cancer and Potential Mechanisms of Oncogenesis
Current Cancer Drug Targets The Extracellular Matrix Regulates Cancer Progression and Therapy Response: Implications for Prognosis and Treatment
Current Pharmaceutical Design <sup>89</sup>Zr-PET Radiochemistry in the Development and Application of Therapeutic Monoclonal Antibodies and Other Biologicals
Current Topics in Medicinal Chemistry Histone Deacetylase Inhibitors as Potent Modulators of Cellular Contacts
Current Drug Targets